Hidradenitis Suppurativa (HS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Hidradenitis Suppurativa Pipeline Drugs Analysis Report Overview
Hidradenitis suppurativa (HS) is also known as Verneuil’s disease or acne inverse. It is a chronic, inflammatory, debilitating skin disease that is characterized by the recurrent development of painful nodules and abscesses that rupture. This leads to the formation of sinus tracts and scarring on the skin. The exact cause of HS is unknown, and it is hypothesized that genetic and environmental factors are the key causes of the disease.
The HS marketed and pipeline drugs market research report provides a data-driven overview of the current and future competitive landscape in HS therapeutics. This report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing, and reimbursement, late-stage pipeline products with phase transition success rate (PTSR), and the likelihood of approval (LoA) for HS.
Leading Marketed Drugs for HS
Significant unmet demand exists in HS because there is only one FDA-approved drug, Humira (adalimumab), available for the treatment of HS, and it is only used in severe cases. It comes under the TNF inhibitors therapy class.
HS Marketed Drugs Segmentation by Mechanism of Action
Some of the key mechanisms of action for HS marketed drugs are biological factor inhibitor, protein and peptide inhibitor, enzyme inhibitor, cell and cell organelle inhibitor, and ligand inhibitor. Most marketed drugs for HS are either biological factor inhibitor or protein and peptide inhibitor.
HS Marketed Drugs Analysis, by Mechanism of Action
For more MoA insights into the HS marketed drugs, download a free report sample
HS Marketed Drugs Segmentation by Routes of Administration
The key routes of administration for HS marketed drugs are injection, oral, and topical. Injection leads the HS marketed drugs in RoA terms.
HS Marketed Drugs Analysis, by Routes of Administration
For more RoA insights into the HS marketed drugs, download a free report sample
HS Marketed Drugs Segmentation by Molecule Type
Most of the marketed drugs for HS are small molecules. Biologics is another significant molecule type in the marketed drugs for HS.
HS Marketed Drugs Analysis, by Molecule type
For more molecule type insights into the HS marketed drugs, download a free report sample
Leading Pipeline Drugs for HS
Some of the leading pipeline drugs of HS are Secukinumab, Bimekizumab, Apremilast, Guselkumab, Upadacitinib, Remibrutinib (LOU064), Iscalimab, Avacopan, and Spesolimab.
HS Pipeline Drugs Segmentation by Mechanism of Action
Some of the key mechanisms of action for HS pipeline drugs are biological factor inhibitor, enzyme inhibitor, receptor antagonists, protein & peptide inhibitor, and cell and cell organelle disruptor. Biological factor inhibitor lead the MoA segment.
HS Pipeline Drugs Analysis, by Mechanisms of Action
For more MoA insights into the HS pipeline drugs market, download a free report sample
HS Pipeline Drugs Segmentation by Routes of Administration
The key routes of administration for HS pipeline drugs are injection, oral, topical, suppository, and inhalational. Injection leads the RoA segment.
HS Pipeline Drugs Analysis, by Routes of Administration
For more routes of administration insights for HS pipeline drugs market, download a free report sample
HS Pipeline Drugs Segmentation by Molecule Type
The HS pipeline drugs comprise mostly biologics and small molecules. Most drugs in development for the treatment of HS are biologics.
HS Pipeline Drugs Analysis, by Molecule Types
For more molecule type insights into the HS pipeline drugs, download a free report sample
Top Sponsors in the HS Marketed and Pipeline Drugs Market
Some of the top sponsors in the HS marketed and pipeline drugs market are Pfizer Inc, Abbvie Inc, UCB SA, Novartis AG, InflaRx Nv, and CSL ltd among others.
HS Marketed Drugs Report Overview
Key Mechanisms of Action | Biological Factor Inhibitor, Protein and Peptide Inhibitors Enzyme Inhibitor, Cell and Cell Organelle Inhibitor, and Ligand Inhibitor |
Key Routes of Administration | Injection, Oral, and Topical |
Key Molecule Types | Small Molecule and Biologics |
HS Pipeline Drugs Report Overview
Key Mechanisms of Action | Biological Factor Inhibitor, Enzyme Inhibitor, Receptor Antagonist, Protein & Peptide Inhibitor, and Cell and Cell Organelle Disruptor |
Key Routes of Administration | Injection, Oral, Topical, Suppository, and Inhalational |
Key Molecule Types | Biologics and Small Molecule |
Top Sponsors (Marketed and
Pipeline Drugs) |
Pfizer Inc, Abbvie Inc, UCB SA, Novartis AG, InflaRx Nv, and CSL ltd |
Scope
GlobalData’s HS Marketed and Pipeline Drugs Assessment, Clinical Trials, and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Retail or Manufacturer Price of Products
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the HS market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HS market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
What are the key mechanisms of action for HS marketed drugs?
Some of the key mechanisms of action for HS marketed drugs are biological factor inhibitor, protein and peptide inhibitor, enzyme inhibitor, cell and cell organelle inhibitor, and ligand inhibitor.
-
What are the key routes of administration for HS marketed drugs?
The key routes of administration for HS marketed drugs are injection, oral, and topical.
-
What are the key molecule types for HS marketed drugs?
The key molecule types for HS marketed drugs are small molecule and biologics.
-
What are the key mechanisms of action for HS pipeline drugs?
Some of the key mechanisms of action for HS pipeline drugs are biological factor inhibitor, enzyme inhibitor, receptor antagonists, protein & peptide inhibitor, and cell and cell organelle disruptor.
-
What are the key routes of administration for HS pipeline drugs?
The key routes of administration for HS pipeline drugs are injection, oral, topical, suppository, and inhalational.
-
What are the key molecule types for HS pipeline drugs?
The HS pipeline drugs comprises of biologics and small molecule.
-
Who are the top sponsors for the HS marketed and pipeline drugs market?
Some of the top sponsors for the HS marketed and pipeline drugs market are Pfizer Inc, Abbvie Inc, UCB SA, Novartis AG, InflaRx Nv, and CSL ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.